Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Sell

Wall Street Data Solutions Rating

Neutral

B

Phathom Pharmaceuticals, Inc. Common Stock (PHAT)

Pharmaceutical Preparations

https://www.phathompharma.com

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

100 CAMPUS DRIVE,, SUITE 102
FLORHAM PARK, NJ

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/25/2019

Market Cap

743,733,120

Shares Outstanding

57,250,000

Weighted SO

57,252,519

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

DAWN --.--%

BPMC --.--%

LYRA --.--%

CGEM --.--%

ABOS --.--%

XFOR --.--%

INZY --.--%

VECT --.--%

KNSA --.--%

Beta

0.6810

Last Div

0.0000

Range

6.065-15.524

Chg

-0.6250

Avg Vol

651595

Mkt Cap

743733120

Exch

NASDAQ

Country

US

Phone

877 742 8466

DCF Diff

8.3229

DCF

4.7821

Div Yield

0.0000

P/S

74.9882

EV Multiple

-3.9134

P/FV

-3.1254

Div Yield %

0.0000

P/E

-2.4597

PEG

-0.0792

Payout

0.0000

Current Ratio

6.4836

Quick Ratio

6.4373

Cash Ratio

5.8763

DSO

400.2929

DIO

467.4147

Op Cycle

867.7076

DPO

1643.7882

CCC

-776.0806

Gross Margin

0.8286

Op Margin

-25.4878

Pretax Margin

-29.9567

Net Margin

-29.9567

Eff Tax Rate

0.0313

ROA

-0.9303

ROE

2.5133

ROCE

-0.9281

NI/EBT

1.0000

EBT/EBIT

1.1753

EBIT/Rev

-25.4878

Debt Ratio

1.5851

D/E

-2.1650

LT Debt/Cap

1.8932

Total Debt/Cap

1.8584

Int Coverage

-108.6793

CF/Debt

-0.4256

Equity Multi

-1.3659

Rec Turnover

0.9118

Pay Turnover

0.2220

Inv Turnover

0.7809

FA Turnover

3.4642

Asset Turnover

0.0311

OCF/Share

-3.6793

FCF/Share

-3.7049

Cash/Share

4.7173

OCF/Sales

-21.7233

FCF/OCF

1.0070

CF Coverage

-0.4256

ST Coverage

-20.2683

CapEx Coverage

-143.6347

Div&CapEx Cov

-143.6347

P/BV

-3.1254

P/B

-3.1254

P/S

74.9882

P/E

-2.4597

P/FCF

-3.4281

P/OCF

-3.3920

P/CF

-3.3920

PEG

-0.0792

P/S

74.9882

EV Multiple

-3.9134

P/FV

-3.1254

DPS

0.0000

Latest Headlines (EST)

Benzinga Jan 05, 13:52 "Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales

Revenue Product Segmentation

a